Project Grant P20AP00037

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $460,000 Cooperative Agreement under the "Multiple Approaches to Support Young Breast Cancer Survivors and Metastatic Breast Cancer Patients" (CFDA 93.376) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. This five-year award (9/30/2024 - 9/29/2029) will support DFCI's efforts to increase support for caregivers and families, raise awareness of clinical trials, and improve quality of...

This $638,903 federal Cooperative Agreement award, granted by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to validate a novel prognostic biomarker for human papillomavirus-positive (HPV+) oropharyngeal cancer (OPC). The project, led by the Washington University in St. Louis, seeks to validate the "HPVHet" biomarker across over 1,000 diverse HPV+ OPC patients from the U.S., Europe, and...

The National Association of Chronic Disease Directors, Inc. (NACDD) was awarded a $460,000 Cooperative Agreement by the Centers for Disease Control and Prevention (CDC) under the "Multiple Approaches to Support Young Breast Cancer Survivors and Metastatic Breast Cancer Patients" program (CFDA 93.376). The funding supports comprehensive services to increase support for caregivers and families, raise awareness of clinical trials, and improve quality of life for young breast cancer...

This Project Grant award from the National Cancer Institute (NCI), under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to determine barriers leading to inferior survival for Black and Hispanic patients with Hodgkin lymphoma. The $589,591 award, granted on February 1, 2025, will fund a 5-year study by the University of Florida to: Examine differences in the receipt and quality of Hodgkin lymphoma treatment for initial diagnosis and relapse. Examine the...

The U.S. Defense Health Agency awarded a $1,056,000.00 Project Grant to the Beckman Research Institute of the City of Hope, a nonprofit organization, to conduct research on PP2A as a promising biomarker and therapeutic target in small cell lung cancer. The grant period runs from September 1, 2023 to August 31, 2026 under the Military Medical Research and Development program (CFDA 12.420). The Beckman Research Institute, which has prior experience collaborating on federal health research...

The National Center for Chronic Disease Prevention and Health Promotion, part of the U.S. Centers for Disease Control and Prevention (CDC), awarded a $460,000 Cooperative Agreement to the Young Survival Coalition, Inc. under the "Multiple Approaches to Support Young Breast Cancer Survivors and Metastatic Breast Cancer Patients" (CFDA 93.376) federal grant program. This five-year award, running from September 30, 2024 to September 29, 2029, will support the Young Survival Coalition in...

This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,759,500.00 to Baylor College of Medicine in Houston, Texas to support research aimed at "Creating Cures for Patients with Langerhans Cell Histiocytosis." The award, which runs from September 1, 2024 to August 31, 2028, will enable Baylor to conduct innovative biomedical studies to develop new treatments and therapies for this rare genetic...

The federal Cooperative Agreement award, totaling $1,379,961.00 and effective from September 30, 2024 to September 29, 2029, is provided by the National Center for Chronic Disease Prevention and Health Promotion, a civilian agency within the U.S. Department of Health and Human Services. The award supports the federal grant program titled "Multiple Approaches to Support Young Breast Cancer Survivors and Metastatic Breast Cancer Patients" (CFDA 93.376). The program aims to increase...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...

This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...